HIMSHims & Hers Health, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~30% a year FCF growth. The price demands less than its three-year revenue growth of 54% a year, expectations look modest.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What HIMS's price assumes
Hims & Hers Health, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.94× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.81%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +30%
Growth the price implies · The price pays for +30% free cash flow growth a year for a decade; revenue has grown +54% a year over the last three.
- Price / book
- 23.4
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 23.4
- EV / EBIToperating margin −6.0%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $62M
- Market capitalisation
- $7.57B
- 3-year revenue growth
- +54%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #36 of 41 by RyuScore